Medigene AG, of Martinsried, Germany, established a clinical trial agreement with Leiden University Medical Center to conduct a phase I study of MDG-1021, a T-cell receptor modified T-cell therapy targeting the HA-1 antigen. The study is scheduled to start in 2020.